• Skip to primary navigation
  • Skip to main content
BC

biochimica clinica

etdal

Impact on laboratory medicine of transitioning from COVID-19 pandemic to “tripledemic”

February 28, 2023 by etdal

Filed Under: In evidenza, N.1 March 2023 1-120 Tagged With: influenza, Respiratory Syncytial Virus, SARS-CoV-2

Big data e intelligenza artificiale in medicina di laboratorio
Artificial intelligence and big data in laboratory medicine

February 28, 2023 by etdal

Filed Under: In evidenza, N.1 March 2023 1-120 Tagged With: etica, sistemi esperti, sistemi informatici di laboratorio

Indicazioni per l’armonizzazione degli intervalli di riferimento nel monitoraggio terapeutico di farmaci antiepilettici
Recommendations for the harmonization of reference intervals in the therapeutic monitoring of antiepileptic drugs

February 28, 2023 by etdal

Filed Under: N.1 March 2023 1-120 Tagged With: farmaci antiepilettici, intervalli di riferimento, monitoraggio terapeutico

La nuova equazione Chronic Kidney Disease Epidemiology Consortium (CKD-EPI) senza la correzione per l’etnia per la stima del filtrato glomerulare: è applicabile in Europa? La posizione della European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)
The new, race-free, Chronic Kidney Disease Epidemiology Consortium (CKD-EPI) equation to estimate glomerular filtration rate: is it applicable in Europe? A position statement by the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

February 28, 2023 by etdal

Filed Under: N.1 March 2023 1-120 Tagged With: chronic kidney disease epidemiology consortium (CKD-EPI), equation, estimated glomerular filtration rate (eGFR)

Variability of cardiac troponin levels in normal subjects and in patients with cardiovascular diseases: analytical considerations and clinical relevance. A consensus document by the Study Group on Cardiac Biomarkers from Italian Society of Biochemical Chemistry (SIBioC) and European Ligand Assay Society (ELAS)

February 28, 2023 by etdal

Filed Under: In evidenza, N.1 March 2023 1-120 Tagged With: biological variation, cardiovascular risk, immunoassay methods

Standardizzazione e armonizzazione dell’albuminuria: a che punto siamo?

February 28, 2023 by etdal

Filed Under: N.1 March 2023 1-120

Grandi novità per LTO nel 2023

February 28, 2023 by etdal

Filed Under: N.1 March 2023 1-120, Senza categoria

A rare case of gamma heavy-chain disease highlighting the need of a comprehensive evaluation of laboratory data

February 28, 2023 by etdal

Filed Under: Case reports, N.1 March 2023 1-120, Senza categoria Tagged With: gamma-chain disease, Heavy-chain disease, laboratory medicine

Due pazienti fragili in Pronto Soccorso: il ruolo del laboratorio nel monitoraggio della terapia con anticoagulanti orali ad azione diretta
Two frail patients in the Emergency Room: the laboratory role in the monitoring of the direct anticoagulants therapy

February 28, 2023 by etdal

Filed Under: Case reports, N.1 March 2023 1-120 Tagged With: dabitagran, DOAC, monitoraggio terapeutico dei farmaci

March 2023

February 28, 2023 by etdal

Filed Under: 2023 V.47

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 92
  • Page 93
  • Page 94
  • Page 95
  • Page 96
  • Interim pages omitted …
  • Page 106
  • Go to Next Page »